• In the current study we report the

  2022-01-03

  

  In the current study, we report the properties of P. anserina mutants carrying mutations in a gene encoding the bi-functional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2). This enzyme catalyzes two opposite reactions (Pilkis et al., 1995, Rider et al., 2004): synthesi

• Earlier we have showed that tumor associated sFas

  2022-01-03

  

  Earlier we have showed that tumor associated sFas mRNA isoform profile and splicing factors expression levels in solid tumors do not correspond to profiles that are observed in cell lines [45]. In the present study, for the first time we show that Fas but not Rac1 pre-mRNA's alternative splicing is

• Here we dissect X chromosome dosage compensation DC in

  2022-01-03

  

  Here, we dissect X chromosome dosage compensation (DC) in C. elegans to determine the effect of chromatin modifications on higher-order chromosome structure during long-range gene regulation. DC is exemplary because it controls hundreds of genes simultaneously, it distinguishes X chromosomes from au

• br Acknowledgments This study was financially

  2022-01-03

  

  Acknowledgments This study was financially supported by National Science Center Poland grant No DEC-2011/02/A/NZ4/00031 (KKK), Jagiellonian University Medical College (Poland) grants: K/ZDS/007130 (SM) and K/ZDS/007131 (SM), COST Action CA15135 (DŁ, HS, KKK) and DFG INST 208/664-1 FUGG (HS). Than

• In conclusion re evaluation of HER status is

  2022-01-03

  

  In conclusion, re-evaluation of HER2 status is necessary to determine the appropriate use of anti-HER2–targeted therapy beyond disease progression. EGFR and c-met amplification, as well as PIK3CA mutation, are rarely associated with acquired resistance. Our results highlight the importance of formal

8705 records 581/581 page Previous First page 上5页 581